Objectives: To compare postoperative lung function and volume compensation in lung cancer patients after lobectomy or segmentectomy. Methods: We retrospectively reviewed patients who underwent initial lung cancer surgery between 2019 and 2021. Of 1076 patients, 870 underwent lobectomy and 206 segmentectomy. Propensity score matching (PSM) of 1:2 was performed using age, sex, smoking status, and preoperative pulmonary function tests (PFTs). Total lung volume (TLV) was calculated using deep learning-assisted 3D lung segmentation on thin-section computed tomography images. Postoperative lung volumes were compared with predicted postoperative (PPO) volumes and correlated with PFT results. Results: After matching, 378 lobectomy and 189 segmentectomy patients were included. TLV reduction was similar between groups, but contralateral lung volume (CLV) increased more after lobectomy (P = .010). Diffusing capacity of the lung for carbon monoxide was better preserved after segmentectomy (P = .029), whereas force vital capacity and forced expiratory volume in 1 second (FEV1) were similar. Actual postoperative PFT values exceeded predicted values in both groups, but the discrepancy was larger after lobectomy (P < .001). In segmentectomy, single-segment resection showed no compensation, while multiple-segment resections had variable compensation patterns. Ipsilateral lung volume changes contributed more than CLV changes, and compensation patterns varied by lobe. The TLV change correlated with forced vital capacity and FEV1 but not diffusing capacity of the lung for carbon monoxide. Conclusions: Lobectomy induced greater CLV compensation than segmentectomy. Although overall lung function preservation was similar, lobectomy resulted in a greater difference between actual and PPO pulmonary function.
Background: The potential association between preoperative percutaneous transthoracic needle biopsy (PTNB) and pleural recurrence in lung cancer remains controversial. This study aimed to determine whether PTNB increases the risk of pleural recurrence in patients with clinically diagnosed stage I non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 1,733 patients with clinical stage I NSCLC who underwent surgical resection between January 2018 and December 2020. Patients were divided into the PTNB group (n=699) and the non-PTNB group (n=1,034). After 1:1 propensity score matching (PSM), risk factors for pleural recurrence were assessed using Fine-Gray subdistribution hazard models. Cumulative incidence rate and overall survival (OS) were also analyzed. Results: After matching, 530 patients were included in each group. Multivariate Fine-Gray analysis revealed that PTNB [subdistribution hazard ratio (sHR) =3.74; 95% confidence interval (CI): 1.06–13.20; P=0.040] and visceral pleural invasion (VPI) (sHR =3.12; 95% CI: 1.10–8.90; P=0.03) were independent risk factors for isolated pleural recurrence, whereas lymphatic invasion was not (sHR =2.32; 95% CI: 0.82–6.56; P=0.11). For all types of recurrence, PTNB, VPI, and lymphatic invasion were significant predictors (all P<0.05). A subgroup analysis was conducted in patients without VPI or lymphatic invasion (n=1,142; PTNB group =332, non-PTNB group =810), representing a low-risk cohort for pleural recurrence. After PSM, 320 patients were included in each group with well-balanced baseline characteristics. In this subgroup, PTNB remained a significant risk factor for isolated pleural recurrence in the univariate Fine-Gray analysis (sHR =2.29; 95% CI: 1.19–4.38; P=0.01) and for all recurrence types (sHR =2.13; 95% CI: 1.13–4.01; P=0.01). Pathologic tumor size was also consistently associated with increased recurrence risk. In multivariate models PTNB, non-adenocarcinoma histology, and larger pathological tumor size were associated with both isolated pleural and overall recurrence (all P<0.001). Conclusions: Preoperative PTNB was statistically correlated with an increased pleural recurrence in clinical stage I NSCLC, even among patients without conventional high-risk pathological features. Careful consideration is warranted when deciding on PTNB for early-stage disease.
Background: Neoadjuvant chemotherapy is generally recommended for locally advanced, potentially resectable thymic epithelial tumors. However, neoadjuvant chemoradiotherapy has been proposed as an alternative approach, potentially achieving higher complete resection rates. In this study, a retrospective analysis was conducted to compare the outcomes of neoadjuvant chemoradiotherapy (NCRT) and neoadjuvant chemotherapy (NCT). Methods: From 2009 to 2022, a total of 98 patients who underwent surgery following either NCRT (n = 30) or NCT (n = 68) for thymic epithelial tumors were included in this study. Propensity score matching was applied, resulting in two matched groups of 30 patients each. The primary endpoint was the comparison of complete (R0) resection rates between the groups. Results: In the matched cohort, the R0 resection rate was significantly higher in the NCRT group (93.3%) compared to the NCT group (73.3%; p = 0.038). The tumor regression grade was also significantly lower in the NCRT group (p = 0.002). However, no significant difference was observed in 5-year overall survival between the groups, either in patients with thymoma (100% for NCRT vs. 90.9% for NCT; p = 0.34) or thymic carcinoma (74.3% for NCRT vs. 63.2% for NCT; p = 0.82). For patients with initial local recurrence, both the 5-year overall survival and post-recurrence survival rates were 100%. Conclusions: The neoadjuvant chemoradiotherapy group demonstrated superior local control, as evidenced by improved tumor regression grades and complete resection rates. However, the absence of corresponding improvement in overall survival warrants further investigation with a larger patient cohort and a longer follow-up period.